| To: StockDung who started this subject | 10/25/2003 12:56:12 AM | | From: scion | | | | Common Colds Patents of George A. Eby
coldcure.com
All of these patents are available for assignment as a single package.
Cure for Common Cold U.S. Patent 5,409,905
PTO Full text of U.S. Patent Number 5,409,905 issued Apr. 25, 1995 (Cure for Common Cold)
European Patent Application will issue soon!!!! (Flavor Stable Zinc Acetate Compositions for Oral Absorption with common cold treatment claim) available to be nationalized for Austria, Belgium, Denmark, France, Germany, Great Britain, Italy, Netherlands, Sweden, Switzerland/Liechtenstein.
Flavor Stable Zinc Acetate Compositions for Oral Absorption Canadian patent number 2,099,670 granted March 30, 1999.
U. S. Patent Number 5,286,748 issued Feb. 15, 1994 (General Method of Shortening the Duration of Common Colds by Application of Medicaments to Tissues of Oral Cavity)
U. S. Patent Number 5,095,035 issued Mar. 10, 1992 (Flavor Stable Zinc Acetate Compositions for Oral Absorption)
U. S. Patent Number 5,002,970 issued Mar. 26, 1991 (Flavor Masked Ionizable Zinc Compositions for Oral Absorption)
U. S. Patent Number 4,956,385 issued Sep. 11, 1990 (Method for Reducing the Duration of the Common Cold [improved])
The above U.S patents and Canadian patent are non-exclusively licensed and commercialized and can be assigned.
U. S. Patent Number Re. 33,465 issued Nov. 27, 1990 (Method of Reducing the Duration of Common Colds - a reissue of U.S. Patent Number 4,503,070) This patent has expired.
This is a public health warning to innovators trying to capitalize on these discoveries without tresspassing on these patents. Seeing and understanding what to expect from other zinc lozenges is mandatory viewing. Did you know that zinc citrate lozenges or any zinc lozenges containing citric acid can make colds worse? Even eating an orange while using the above patented lozenges can worsen colds. Citric acid and zinc are toxic when allowed to be absorbed into the oral tissues, but not when swallowed as a tablet and dissolution occurs in the stomach. |
| | MTXX FORMERLY GUMM. CURE OR OUTRIGHT SCAM? | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: StockDung who started this subject | 10/25/2003 1:06:34 AM | | From: scion | | | | United States Patent 5,409,905
Eby, III * April 25, 1995
--------------------------------------------------------------------------------
Cure for commond(sic) cold
Abstract
Present invention is a non-toxic, flavor stable, pleasant tasting composition releasing Zn.sup.2+ from compositions containing a highly ionizable zinc compound other than zinc gluconate that reduces the duration of common colds in humans. The composition is used in the oral cavity of a human suffering from a common cold. The composition comprises highly ionizable zinc compounds and a pharmaceutically acceptable carrier such as fructose, dextrose or sucrose with various additions. Compositions are unique in that they are non-toxic, pleasant tasting and do not have an offensive aftertaste, yet deliver zinc ions into oral tissues which may be used to treat common colds, reduce the duration of common colds or cure common colds in humans in need of such treatment. Compositions are non-toxic, thermally, chemically and flavor stable. The compositions may be prepared in the form of compressed tablets, lozenges, powders, liquids or chewing gums. Present compositions deliver strongly antirhinoviral and interferon inducing Zn.sup.2+ ions to the oral mucosa of a human. In vitro, Zn.sup.2+ is as antirhinoviral and as protective of cell monolayers as interferon and is also a potent interferon inducer. Said pleasant tasting composition is an improvement upon a slow-release candy composition comprising a hard candy base, highly ionizable zinc compounds and an amino acid; and said composition is an improvement upon a medicinal composition for release of zinc ion consisting essentially of a suitable pharmaceutical carrier, highly ionizable zinc compounds and anethole.
--------------------------------------------------------------------------------
Inventors: Eby, III; George A. (2109 Paramount Ave., Austin, TX 78704)
[*] Notice: The portion of the term of this patent subsequent to March 10, 2009 has been disclaimed.
Appl. No.: 215008
Filed: March 21, 1994
PRIMARY OBJECTIVE AND GENERAL DESCRIPTION OF INVENTION
Accordingly, it is a primary objective of this invention to disclose and claim improved solid oral zinc compositions that are non-toxic, thermally, chemically, and flavor stable. Said compositions shall be devoid of the objectionable flavor and aftertaste commonly associated with oral zinc gluconate compositions. Said compositions shall be intended to release Zn.sup.2+ ions into oral and oropharyngeal mucous membranes for local absorption and movement through BCECs into the nose. Said compositions are primarily intended to be used to reduce duration of common colds or their symptoms, management of upper respiratory allergy, for nutritional support or for related purposes. Said compositions shall contain one or more highly ionizable zinc compounds, excluding zinc gluconate, which have been discovered by this inventor to be non-toxic and not to have an objectionable taste or aftertaste when properly formulated. These primary objectives and other objectives of this invention will be found apparent from the following general description and detailed examples.
Compositions Containing Highly Ionizable Zinc Compounds Generally
This inventor discloses and claims non-toxic, flavor-stable, pleasant tasting solid oral compositions specifically containing highly ionizable zinc compounds and pharmaceutically acceptable carriers for use primarily in human common cold treatment, upper respiratory allergy management and for nutritional support. Said compositions are intended to be dissolved in the mouth, masticated or otherwise used in the mouth to release Zn.sup.2+ ions into the tissues of the oral cavity and oropharyngeal tissues of humans. Said highly ionizable zinc compounds are to be slowly and uniformly released by aqueous dissolution of solid ingredients within said solid oral composition, as said compositions are held or retained in the mouth. Saliva, generated by the person orally dissolving said composition, is the usual source of said aqueous solvent. Ideal oral cavity retention time periods are 30 minutes per application or use of composition. Soft candy and chewing gums are to release highly ionizable zinc compounds slowly over a sustained period of time.
Said highly ionizable zinc compositions are believed non-toxic as they release essentially 100% of their zinc as Zn.sup.2+ at oral tissue pH 7.4 and at lower pit values. Zn.sup.2+ is not believed to be absorbed into the interior of cells, and Zn.sup.2+ exerts its beneficial effects solely on the cell membrane, perhaps by sealing the membranes so that virally infected cells do not release theft viruses extracellularly. Lipophilic complexes of zinc and neutral charged zinc species at pH 7.4 may be cytotoxic when absorbed into cells which may worsen common colds through increased tissue damage, particularly oral tissue damage. Negatively charged zinc complexes at pH 7.4 may also be toxic and may similarly increase the duration and severity of colds. Such may have been the cause of increased severity and duration of colds in the Farr et al 1987 study and the Douglas et al. 1987 study which released negatively charged zinc and neutral zinc complexes.
Invented compositions of highly ionizable zinc compounds are stable, meaning that negligible degradation in flavor, appearance or chemistry occured in tested compositions under extended multi-year storage in normal and near normal temperature conditions while sealed in air-tight, opaque containers. Compositions of said highly ionizable zinc compounds are non-toxic, pleasant tasting and have a pleasant aftertaste, generally defined by the ligand, the added flavors, the pharmaceutically acceptable carrier, or by added super sweeteners such as saccharin. Said compositions are an improvement upon a slow-release candy composition comprising a hard candy base, zinc gluconate and an amino acid, as said sweet compositions of the present invention exclude zinc gluconate and amino acids; and whereby said compositions are improvements upon a medicinal composition for release of zinc ions consisting essentially of a suitable pharmaceutical carrier, zinc compounds and anethole; as present composition excludes anethole.
As discovered from said thermal and aging stability studies, compositions are nontoxic, usually without an objectionable taste or aftertaste even without an added flavor-mask. Compositions are non-toxic, chemically, thermally and flavor stable with no increase in bitterness under high summer-time temperature conditions over multi-year periods of time. This invention primarily discloses and claims the discovery of non-toxic, pleasant tasting and aftertaste-free compositions of highly ionizable zinc compounds dispersed in a consumable pharmaceutically acceptable carrier that reduce the duration of common colds. By necessity to clearly and more fully describe said compositions, said inventive compositions include:
Oral compositions containing highly ionizable zinc compounds in any pharmaceutically acceptable carrier such as fructose, Mendell's Sugartab.RTM., Sweetrex.RTM. or Emdex.RTM., sucrose, dextrose, maltose, lactose, sweetened water and the like, singularly or in combination, with following pharmaceutical necessities included singularly or in combination, as desired:
tablet binders for compressed tablets, lozenges and troches including polyethylene glycol-6000 or 8000,
flavor oils such as peppermint, methyl salicylate, menthol and eucalyptol excluding anethole, as disclosed by U.S. Pat. No. 5,002,970.
flavor oil stabilizers, including spray driers and cyclodextrins,
coloring agents and dyes,
glidants, including silica gel,
tablet lubricants, including magnesium stearate,
other necessities excluding amino acids as disclosed in U.S. Pat. No. 4,684,528;
and with the following medicinal additives included as desired or necessary:
antiviral agents, including antirhinoviral agents,
antimycoplasmal agents,
antibiotics,
nasal decongestants,
antihistamines,
antinausea agents,
analgesics,
cough relievers,
dental desensitizers,
saliva inhibitors,
vitamins, including ascorbic acid,
minerals, other than zinc, and
other medicinal agents and nutritional supplements either directly incorporated within compositions or chemically isolated through techniques including micro-encapsulated and inclusion within cyclodextrins. Micro-encapsulation with insoluble porous membranes providing a time release capability for ingredients that might interfere with release of zinc ions or adversely affect taste of composition is anticipated.
Such compositions include solid forms such as tablets, troches, lozenges and powders; chewable forms such as chewing gums and soft candies; and liquid forms such as syrups, mouth washes and sprays. When said compositions are applied to oral and oropharyngeal membranes of a human, they are non-toxic, meaning that they are not absorbed into cells in a manner which causes cytotoxicity at the concentrations used in the oral composition, palatable, without undesirable taste or unpleasant aftertaste, yet they allow oral and oropharyngeal absorption of Zn.sup.2+ ions. When compositions are to be used to treat common colds, reduce the duration of common colds or cure common colds, said pharmaceutical necessities and medicinal additives shall not be present in sufficient quantities to impair the beneficial action of Zn.sup.2+ on the duration of common colds or they shall be sealed through micro-encapsulation.
Highly Ionizable Zinc Compounds
For purpose of this invention highly ionizable zinc compounds include all highly soluble, non-toxic inorganic and organic complexes of zinc excluding zinc gluconate having a first stability constant less than about log K.sub.1 =2. Inorganic highly ionizable complexes of zinc include zinc chloride (log K.sub.1 =0.0) and zinc sulfate, both of which are Generally Recognized As Safe (GRAS) as well as other inorganic zinc complexes having a first stability constant of zinc of less than about log K.sub.1 =2. Organic highly ionizable zinc complexes having a first stability constant of less than log K.sub.1 =1.0 are preferred and include zinc propionate, zinc butyrate, zinc n-butyrate, zinc beta-hydroxybutyrate, zinc benzoate, zinc formate and zinc acetate. Said preferred zinc complexes all have sufficiently low first stability constants (log K.sub.1 =0 to 1) that zinc exists essentially as 100% Zn.sup.2+ ions at aqueous solution at pH 7.4. Zinc succinate and zinc sulfate are slightly less ionizable and are also preferred complexes of zinc.
Although zinc gluconate is the best known source of Zn.sup.2+ ions in lozenges for treating common colds, highly soluble, highly ionizable zinc compounds other than zinc gluconate merit special attention. For purposes of this invention, zinc lozenges for treating common colds, curing common colds or reducing the duration of common colds contain between about 0.2 and 500 mg zinc and more often contain about 2 to 50 mg of zinc and most often contain about 10 to 23 mg zinc from a highly ionizable zinc compound excluding zinc gluconate dispersed in about 1 to 15 grams of a pharmaceutically acceptable carrier, and preferably a sweet pharmaceutically acceptable carrier. Highly soluble, highly ionizable zinc compounds offers improved, unexpected characteristics over zinc gluconate that require close attention.
Surprising and Unexpected Taste Characteristics
Undiluted highly ionizable zinc compounds have dreadful, vile tastes and some have sharp disagreeable odors. Most important, surprising, totally unexpected, and patently unique; any non-toxic highly ionizable zinc compound other than zinc gluconate sufficiently diluted with any pharmaceutically acceptable carrier, such as sweetened water, fructose, sucrose, dextrose, starch, lactose, other sugars or other dilutants, has neither the seriously offensive taste nor the long lasting 24 to 60 hour bitter and offensive aftertaste like that present with zinc gluconate when said compositions are retained in the oral cavity of a human for sustained periods of time (defined as 5 to 30 minutes or more). Highly ionizable zinc compounds may be sufficiently diluted, yet sufficiently concentrated to be of utility against common colds when applied over such extended time. Properly prepared compositions have a pleasant taste and pleasant aftertaste. All common cold orally absorbed compositions (whether containing Zn.sup.2+ or other antirhinoviral agents) are required to be slowly and uniformly released in a sustained manner into the oral cavity as said composition is being orally consumed or masticated and, said compositions must be non-toxic, stable and have a pleasant taste and aftertaste during composition dissolution. Sustained application of Zn.sup.2+ ions (defined as 5 to 30 minutes or longer per application) to the interior of the mouth including the tongue, oral cavity, throat and oropharyngeal surfaces from a palatable composition releasing a 1 to 50 millimolar concentration of Zn.sup.2+, and preferably about 5 to 15 millimolar concentration, and more preferably about 7 to 10 millimolar concentration for preservation of best taste is necessary in order to be effective in reducing the duration of common colds. This present inventor also discovered that the objectionable taste of highly ionizable zinc compounds is eliminated with addition of consumable, pharmaceutically acceptable carriers such as fructose, sucrose, dextrose and other sugars and sweeteners; with or without added super sweeteners like saccharin and various flavors; all of which is directly contrary to teachings of U.S. Pat. No. 4,684,528.
Fructose, Sucrose and Dextrose as Pharmaceutical Carriers
Fructose is the sweetest of the natural sugars. It is a component of sucrose, a disaccharide, and is an isomer of dextrose, all of which are sugars. Neither fructose, sucrose nor dextrose are believed to chelate zinc in a way that would detract from its utility in treating common colds. The first stability constant of dextrose for Zn.sup.2+ is log K.sub.1 =0.01 [Briggs J. et al. (1981), Carbohydrate Research, 97:181]. It is surprising and unexpected that fructose does not visibly react, change color or form bitter compounds with highly ionizable zinc compounds at higher ambient temperatures as this monosaccharide is a polyhydroxy ketone and is usually considered highly reactive. On the other hand, dextrose, a polyhydroxy aldhyde is normally considered to be an inert monosaccharide. Dextrose reacts with zinc gluconate over time to form extremely bitter complexes, but not with other highly ionizable zinc compounds tested. Various sweet tasting commercial tablet bases having a modified sugar tablet base produce bitter zinc gluconate lozenges after lozenges age for a few weeks, particularly when exposed to high summer temperatures. However, various sugar tablet bases do not become bitter in lozenges when used with those highly ionizable zinc compounds tested by present inventor in lozenges or tablets, regardless of time or temperature.
Favored Compositions of Fructose and Dextrose with Highly Ionizable Zinc Compounds
It can now be revealed that preference is given to compositions of highly ionizable zinc compounds over zinc gluconate in a fructose and agglomerated dextrose based carrier over other sweet carriers. Favored formulation is any highly ionizable zinc compound other than zinc gluconate having a first stability constant of log K.sub.1 =from less than 0 to about 2, and preferably from less than 0 to about 1, in lozenges having a carrier of fructose mixed with agglomerated dextrose. Tablets with crystalline fructose as a carrier could be bound by Mendell's Emdex.RTM. at about one-half the weight of crystalline fructose without tablet capping. Generally lozenges are made in a 2 to 6 gram size to allow a suitable dissolution rate for lozenges. Dissolution time should be about 15 minutes in water bath testers at 37 C. degrees or about 30 minutes when orally dissolved as lozenges for treatment of common colds, common cold symptoms, curing common colds or reducing the duration of common colds. Greatest efficacy occurs when saliva generation is lowest, thus raising Zn.sup.2+ molar concentration in the oral cavity, suggesting utility for incorporating saliva inhibitors into compositions. Increased sweetness and strong flavorings increase salivation which decreases Zn.sup.2+ concentration and efficacy. Smaller and larger lozenges from 0.1 up to 15 grams are anticipated by this invention.
Compressed Tablet Compositions
Lozenges, tablets and troches in this invention are essentially the same, but may differ in shape, size and manufacturing technique. Since fructose is sweeter than sucrose and other sugars, it is preferred for use in direct compression of lozenges containing highly ionizable zinc compounds. Fructose may be processed for direct compression of tablets, troches and lozenges by incorporation of a tablet binder such as PEG-8000, perhaps using fluid bed agglomeration techniques wherein PEG has been diluted with water and the ground fructose crystals are agglomerated with PEG. To make directly compressible lozenges, add highly ionizable zinc compounds to PEG-8000 processed fructose; or add highly ionizable zinc compounds excluding zinc gluconate to crystalline fructose and commercially available, sweet, direct compression products such as Mendell's Sugartab.RTM., Sweetrex.RTM., or Emdex.RTM.. Add saccharin if desired, flavors as desired, glidants such as silica gel as needed, and lubricants such as magnesium stearate as needed. Mixture should be kept dry and tableted soon after mixing. Ingredients are mixed and directly compressed into lozenges, tablets or troches using conventional pharmaceutical mixing and tableting equipment. Compressive force must be sufficient to produce maximum hardness throughout the lozenges to preserve the dissolution rate and maximum efficacy of lozenges in treating common colds or their symptoms, shortening the duration of common colds or curing common colds. Dissolution should occur over a sustained period of time, that being 5 to 30 minutes or more and preferably about 20 to 30 minutes. Store compositions in air tight containers in a cool dark place. If heated to high summer-time room temperatures, compositions, when properly prepared and sealed, are pleasantly flavored, do not turn brown over time and do not have a bitter aftertaste. Although added ingredients are not believed necessary to present a pleasantly flavored composition having no zinc aftertaste, addition of super sweeteners, such as saccharin is anticipated to improve the flavor of the basic composition and added pharmaceutical necessities and medicinal additives.
Liquid Compositions
Highly ionizable zinc compounds with a pleasant tasting, sweet, pharmaceutically acceptable carrier may be prepared in any liquid form such as syrups, mouth washes or sprays with water or other liquids for repeated delivery of concentrated highly ionizable zinc compounds excluding zinc gluconate to oral and oropharyngeal mucous membranes over a sustained period of time, that being 5 to 30 minutes or more and preferably about 20 to 30 minutes, so as to permit a prolonged contact by highly ionizable zinc compounds upon mouth and throat tissues. Said invention differs from zinc chloride mouth washes commercially available as present invention is to be retained in the oral cavity for much longer time than presently available mouth washes to effectively reduce the duration of common colds, treat common colds or cure common colds.
Soft Compositions
Highly ionizable zinc compounds in chewable compositions such as soft candy, gum drop, liquid filled candies, chewing gum base and dental supplies, such as tooth pastes and mouth washes, may be prepared by adding highly ionizable zinc compounds excluding zinc gluconate and sweeteners including fructose, sucrose and saccharin to them as needed. To obtain efficacy against the duration of common colds, to cure common colds or to treat common colds, said soft composition are retained in the mouth over a sustained period of time, that being 5 to 30 minutes or more and preferably about 20 to 30 minutes.
Super Sweeteners
Various super sweeteners including saccharin, aspartame, cyclamates, acesulfame K, neohesperidin dihydrochalcone and other super sweeteners may be added to the carrier in amounts sufficiently low so as not to chemically react with zinc to a therapeutically significant amount of Zn.sup.2+. Preference is given to sodium saccharin, about 1 to 14 mg per 23 mg zinc, as additive super sweetener. Above 50 mg saccharin, compositions may have a bitter saccharin taste and aftertaste.
Flavors
Many flavorings can be added to impart their own flavor including but not restricted to peppermint, peppermint-menthol, eucalyptol, wintergreen, licorice, clove, cinnamon, spearmint, cherry, lemon, orange, lime, menthol and various combinations. Preference is given to peppermint (Bell #113.042) flavor plated onto silica gel for trueness of flavor and multi-year stability.
Stabilized Flavors
Some flavor oils may not be stable in long-term storage with highly ionizable zinc compounds in lozenges, and must be prevented from contacting zinc, evaporating and degrading generally. In lozenges and other dry solid compositions, flavors may be stabilized by spray drying with National Starch's N-Lok or other modified starches, or included within cyclodextrins, and/or coated with PEG 6000 or 8000. Inclusion of flavor oils within cyclodextrins results in essentially complete long-term thermal, oxidative and photo-decomposition stability. Of particular interest, inclusion results in protection against flavor oil degradation and oxidization otherwise accelerated by heat, light and metal salts. Spray dry flavors must not include acacia, and other vegetable gums that are powerful zinc chelators. Highly ionizable zinc compounds excluding zinc gluconate may be coated with PEG 6000, 8000 or higher molecular weight PEG or included within cyclodextrins to prevent contact of zinc with flavors. However, peppermint oil (Bell #113.042) plated onto silica gel (Siloid 244FP) is stable with no loss of flavor or aroma for at least two years in directly compressed highly ionizable zinc compounds lozenges in sealed amber glass bottles, and presumably any air-tight, opaque container.
Pharmaceutically Acceptable Carriers
Without regard to desirability of ingredients or intended use of compositions, a more complete list of sweet, consumable, pharmaceutically acceptable carriers includes but is not limited to: (a) carbohydrates including fructose, sucrose, sugar, dextrose, starch, lactose, maltose, maltodextrins, corn syrup solids, honey solids, commercial tablet compositions including Emdex.RTM., Mor-Rex.RTM., Royal-T.RTM., Di-Pac.RTM., Sugar-Tab.RTM., Sweet-Rex .RTM., New-Tab.RTM., (b) sugar alcohols including mannitol, sorbitol, xylitol, and (c) various relatively insoluble excipients including dicalcium phosphate, calcium sulfate, calcium carbonate, microcrystalline cellulose and other pharmaceutical tableting ingredients. Pharmaceutically acceptable carriers for compositions to be used for treating common colds by release of zinc ions in the oral cavity generally include the above, but preference is given to carriers other than the sugar-alcohols and insoluble ingredients because they lack sufficient sweetness and may adversely affect mouth-feel.
Undesirable Ingredients for Treating Common Colds
Highly ionizable zinc compounds in compositions for treating common colds must exclude positively-charged zinc (Zn.sup.2+) ion-depleting ingredients and other incompatibles. Acacia, super sweeteners, citric acid, tartaric acid and other food acids, lake colors, alkalis and their carbonates, oxalates, phosphates, sulfides, lime water, and vegetable decoctions are considered incompatible with highly ionizable zinc compounds; and may cause compositions to be flavor unstable or cause a loss of efficacy against common colds or both. Zn.sup.2+ ion depleting chelators must not be added in chemically significant amounts even if they are physically isolated from highly ionizable zinc compounds within compositions.
* * * * *
patft.uspto.gov |
| | MTXX FORMERLY GUMM. CURE OR OUTRIGHT SCAM? | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: StockDung who wrote (6) | 10/25/2003 1:43:01 PM | | From: scion | | | | | He's a busy fellow, George. I wonder if he's actually making any money off his efforts? |
| | MTXX FORMERLY GUMM. CURE OR OUTRIGHT SCAM? | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: ravenseye who wrote (9) | 12/8/2005 7:22:21 AM | | From: ravenseye | | | | To: Jeffrey S. Mitchell who wrote (7126) 2/18/2005 1:07:50 PM
From: Jeffrey S. Mitchell Read Replies (1) 7370 of 9093
Re: 2/18/05 - [MTXX] Judge Rules Attorney's Failure to Disclose his Identity on Yahoo Violated the Law....
Message 21060618
To: Jeffrey S. Mitchell who wrote (7651) 4/13/2005 1:21:56 AM
From: Jeffrey S. Mitchell Read Replies (1) 7961 of 9093
Re: 4/6/05 - [MTXX] Radacosky vs. John Doe
Message 21223168
To: Jeffrey S. Mitchell who wrote (7961) 7/15/2005 1:41:36 AM
From: Jeffrey S. Mitchell Read Replies (2) 8685 of 9093
Re: 7/14/05 - [MTXX] Radacosky vs. John Doe: Radacosky Subpoenas Yahoo..
Message 21507468
Z Best Place to Talk Stocks
From: AsturiasPh.D/MBA 7/22/2005 1:57:45 PM
52955 of 52960
Message 21531900
To: Jeffrey S. Mitchell who wrote (8685) 7/22/2005 8:00:33 PM
From: Jeffrey S. Mitchell Read Replies (2)8751 of 9093
Re: 7/20/05 - [MTXX] Radacosky vs. John Doe: Radacosky Subpoenas Additional Information from Yahoo Posters
Message 21533072
12/2/2005 08:30AM CV Mtn: Strike Granted C 12/02/05
12/2/2005 08:30AM CV Mtn: Quash Granted C 12/02/05
superiorcourt.maricopa.gov
7/19/2005 OXS - Order To Extend Time For Service 7/29/2005
NOTE: UNTIL 10/17/05
7/13/2005 322 - ME: Notice Of Intent To Dismiss 7/13/2005
superiorcourt.maricopa.gov
Message 167 of 1759 < Previous Message | Next Message >
From: Floyd3491@...
Date: Sat Jan 10, 2004 1:15 am
Subject: Who is Floyd XXXXXXXXX and why is he interested in Zicam? floydtheonea...
Dear Friends.... In a attempt to silence the truth Matrixx has filed a SLAPP suit against me and has added my wife also to the suit. The suit is located here
superiorcourt.maricopa.gov
health.groups.yahoo.com |
| | MTXX FORMERLY GUMM. CURE OR OUTRIGHT SCAM? | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: scion who wrote (5) | 7/5/2006 6:09:34 PM | | From: StockDung | | | | Study Supports Chicken Soup as a Cold Remedy
Source: American College of Chest Physicians (ACCP) Released: Wed 18-Oct-2000, 00:00 ET
Embargo expired: Tue 17-Oct-2000, 00:00 ET
Printer-friendly Version
Study Supports Chicken Soup as a Cold Remedy
Libraries
Medical News Keywords
CHEST PHYSICIANS MEETING pulmonary disease asthma tuberculosis respiratory
Contact Information
Available for logged-in reporters only
Description
Chicken soup may contain a number of substances with beneficial medicinal activity including an anti-inflammatory mechanism that could ease the symptoms of upper respiratory tract infections. (American College of Chest Physicians, 10-00)
ACCP NEWS RELEASE
For Release: October 17, 2000
NEW STUDY SUPPORTS CHICKEN SOUP AS A COLD REMEDY
Chicken soup may contain a number of substances with beneficial medicinal activity including an anti-inflammatory mechanism that could ease the symptoms of upper respiratory tract infections, according to a new study.
The study was reported in the October issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians.
The suspected benefits of chicken soup were reported centuries ago. The Egyptian Jewish physician and philosopher, Moshe ben Maimonides , recommended chicken soup for respiratory tract symptoms in his writings back in the 12th century which were, in turn, based on earlier Greek writings. However, there's little in the literature to explain the pathophysiology of such benefits.
Colds are often the result of transient infections of the mucosa of the upper respiratory tract from a variety of viruses. While incompletely understood, the viral infection leads to the stimulation of a cytokine cascade. Cytokines are soluble proteins secreted by various cell types and involved in cell-to-cell communication, coordinating antibody and T-cell immune interactions, and amplifying immune reactivity. Many, if not most, symptoms related to colds are likely the result of the inflammatory response initiated by the cytokine cascade. Colds are also associated with the generation of neutrophil chemotactic activities that relate to a cell's tendency to migrate toward or away from certain chemical stimuli. Neutrophils are the circulating white blood cells essential for the processes by which bacteria, cellular debris, and solid particles are removed and destroyed. Since neutrophil products are potent stimulators of mucous release, this may be one mechanism by which colds commonly lead to cough and sputum from infection.
Researchers from the Pulmonary and Critical Care Medicine Section of the Nebraska Medical Center in Omaha, Nebraska initiated a study to evaluate the possibility that chicken soup may be a factor in attentuating the inflammatory response associated with colds. They set out to determine the ability of chicken soup to inhibit neutrophil chemotaxis in response to standard chemotactic stimuli.
The recipe they used was called "Grandma's soup," which not only included chicken, but also onions, sweet potato, parsnips, turnips, carrots, celery stems, and parsley, with the addition of salt and pepper. Many tests were conducted on the soup. For example, to determine which components of the soup contained neutrophil inhibitor activity, samples of chicken and a portion of each of the vegetables were boiled for one hour. The broths then were harvested, frozen, and saved for assay. For comparison purposes, commercially available soups were obtained from a local supermarket and prepared according to the directions on the label.
Stephen Rennard, M.D., FCCP, said the results of the study demonstrate that chicken soup inhibits neutrophil migration to standard stimuli. The inhibitory effect was observed clearly at concentrations without cytotoxicity. Dr. Rennard said: "A variety of soup preparations was evaluated and found to be variably, but generally, able to inhibit neutrophil chemotaxis. The current study, therefore, presents evidence that chicken soup might have an anti-inflammatory activity, namely the inhibition of neutrophil migration."
Researchers noted that the soup used for the majority of experiments, "Grandma's soup," has several unusual features. For one, it contains strained vegetables. Dr. Rennard noted, however, that the inhibitory activity was observed with several other recipes that lack the particles from vegetables. "Thus," he said, "while the identity of the biologically active materials is unknown, it seems likely they are water-soluble or extractable. Pureed carrots or other vegetables are not recommended as a remedy while chicken soup is."
Dr. Rennard also pointed out that this was a laboratory experiment, an in vitro study as opposed to an in vivo clinical study involving human patients. He said: "It was a well-controlled study and used well-established in vitro methods to provide limited evidence that chicken soup could have an anti-inflammatory activity. Since many of the symptoms that follow upper respiratory tract viral infections may well be due to the inflammatory response, the current study may have clinical relevance."
CHEST is published by the American College of Chest Physicians which represents 15,000 members who provide clinical respiratory and cardiothoracic patient care in the United States and throughout the world.
_________________________________________________________________
For a copy of the article in PDF, reporters can access chestnet.org or contact Kimberly Lynch of the ACCP at (847) 498-8341. She can also be reached by email at klynch@chestnet.org.
Dr. Rennard can be reached by calling Vicky Cerino, University of Nebraska Medical Center Public Affairs Office at (402) 559-5190 or by email at vcerino@unmc.edu.
--------------------------------------------------------------------------------
© 2006 Newswise. All Rights Reserved.
|
| | MTXX FORMERLY GUMM. CURE OR OUTRIGHT SCAM? | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: ravenseye | 9/23/2006 10:39:01 PM | | | | | | hey flo, help me fill in the gaps with what we don't know!
lma(zz)o
I need your help flo to understand the following article which states Steve Worthington runs Barbary Coast Capital Management but I didn't see his name in the sec filings. Why not?
lma(zz)o
BusinessWeek online By GARY WEISS
Smiling as Highfliers Blow Up
Short-sellers eye the next batch of overreachers
That is the credo of high-tech maven Steve Worthington, a former venture capitalist who runs Barbary Coast Capital Management in San Francisco. Barbary Coast is a traditional hedge fund that buys stocks as well as shorts them. That distinguishes it from the short-only funds that do nothing but bet against stocks.
businessweek.com
JULY 2, 2001
COVER STORY
Stocks to Avoid: Where the Shorts Are Finding Targets
Steve Worthington, a short and hedge-fund manager at Barbary Coast Capital Management in San Francisco, says he's having no trouble finding stocks poised to plunge,...
businessweek.com
Was Herb Greenberg, the Senior Columnist who wrote 06/20/2002 07:51 AM EDT ...
"Speaking of which, Ernst might want to get its hands on yesterday's 13-page issue of The Eyeshade Report from Forensic Advisors" a subscriber of the The Eyeshade Report?
www.thestreet.com/funds/herbgreenberg_up/10028202.html
lma(zz)o Has Mulligan released the subscriber list?
In the beginning ... John Doe case is still ongoing, isn't that right flo?
CV2002-023934 Case Type Civil File Date 12/12/2002
Matrixx Initiatives Inc Plaintiff
John Doe Defendant Male
superiorcourt.maricopa.gov
From: Floyd3491@...
Date: Sat Jan 10, 2004 1:15 am
Subject: Who is Floyd Schneider and why is he interested in Zicam? floydtheonea...
Dear Friends.
My name is Floyd Schneider and I would like you to know why I have posted so much information on this thread about Zicam. I first became aware of anosmia and Zicam when doing a search on google on the company that markets Zicam Matrixx Initiative Inc. previously known as Gum Tech International. I
started to expose the dangers and warning signs on silicon investor and yahoo mtxx /gumm message boards. In a attempt to silence the truth Matrixx has filed a SLAPP suit against me and has added my wife also to the suit. The suit is located here
superiorcourt.maricopa.gov
More of the post is at: health.groups.yahoo.com
CV2004-001338 Case Type Civil File Date 1/23/2004
Kenneth W Wigton Plaintiff Male Daniel Radacosky
superiorcourt.maricopa.gov
MATRIXX INITIATIVES INC - MTXX Unscheduled Material Events (8-K ...Ms. Remond's article appears on today's Dow Jones Newswire-the very day that Matrixx Initiatives is deposing Schneider. We believe that the timing of this ...
sec.edgar-online.com/2004/02/11/0000950153-04-000327/Section5.asp
Re: 3/2/04 - [MTXX] Dow Jones: Matrixx And A Brokerage Called Gunnallen DJ IN THE MONEY: Matrixx And A Brokerage Called Gunnallen By Carol S. Remond ...
www.siliconinvestor.com/readmsg.aspx?msgid=22281735
CAYMAN ISLANDS
GAZETTE
Monday, 3rd May 2004 Issue No. 9/2004
pdf file page 11 of 55
BARBARY COAST MASTER GENERAL PARTNER LTD.
(In Voluntary Liquidation)
The Companies Law (2003 Revision)
TAKE NOTICE THAT the following resolution was passed by the shareholders of the above-mentioned company by unanimous written resolution dated 8th April 2004:
“RESOLVED that the Company be voluntarily wound up and Stephen N. Worthington be appointed as the Liquidator to act for the purposes of such winding-up.”.NOTICE IS HEREBY GIVEN that the creditors of the above-named Company which is being wound up voluntarily are required within 30 days of this
notice, to send in their names and addresses and the
particulars of their debts and claims and the names and addresses of their attorneys-at-law (if any) to the undersigned. In default thereof, they will be excluded from the benefit of any distribution made before such debts are proved.
Dated this 20th day of April 2004.
STEPHEN N. WORTHINGTON
Voluntary Liquidator
Contact for enquiries: Jarod Benson
Telephone (345) 914 4297
Facsimile (345) 814 8297
Address for service:
Walkers, P.O. Box 265 GT
Grand Cayman, Cayman Islands
The address of the Liquidator is:
c/o Barbary Coast Capital Management, LLC
311 California, Suite 600, San Francisco
CA, 94104, USA
gazettes.gov.ky
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
CAYMAN ISLANDS
GAZETTE
Tuesday, 15th June 2004 Issue No. 12/2004
pdf file page 15 of 38
BARBARY COAST MASTER GENERAL PARTNER LTD.
(In Voluntary Liquidation)
The Companies Law (2003 Revision)
TAKE NOTICE THAT pursuant to section 145 of the Companies Law (2003 Revision) that the final meeting of the shareholders of the above-named company will be held at the office of Walkers, P O Box 265GT, Walker House, Mary Street, George Town, Grand Cayman, Cayman Islands, on 15th July 2004, at 10.00 a.m.
Business:
1. To lay accounts before the meeting, showing how the winding up has been conducted and how the property has been disposed of, as at the final winding up and for hearing any explanation that may be given by the liquidator.
2. To authorise the liquidator to retain the records of the Company for a period of five years from the dissolution of the Company, after which time they may be destroyed.
gazettes.gov.ky
pg 16 of 38
Any member entitled to attend and vote is permitted to appoint a proxy to attend and vote instead of
him and such proxy need to be a member.
Dated this 31st May 2004.
STEPHEN N. WORTHINGTON
Voluntary Liquidator
The address of the Liquidator is:
c/o Barbary Coast Capital Management, LLC
311 California, Suite 600, San Francisco
CA 94104, USA
gazettes.gov.ky
To: rrufff who wrote (6053) 5/27/2004 4:06:39 PM
From: AsturiasPh.D/MBA Read Replies (1) 6056 of 9801
IDN INTELI CHECK SERVED SI WITH A SUBPOENA FOR MY IDENTITY. THEY HAD NOT EVEN FILED A LAW SUIT. SI REFUSED TO HONOR THE SUBPOENA. FUNNY THING WAS ALL THAT I EVER DID WAS POST THIS RESEARCH REPORT ON SI
...see the post for more
Message 20172631
SUPERIOR COURT OF ARIZONA
MARICOPA COUNTY
CV 2002-023934 08/23/2004
Docket Code 005 Form V000A Page 2
LATER:
The Court is in receipt of a letter dated June 17, 2004 from Robert F. Schaberg, on behalf of Barbary Coast Capital Management. The Court will take no action on this letter unless an appropriate motion is filed.
Filed: Letter dated 6/17/04 from Robert F. Schaberg
courtminutes.maricopa.gov
IN THE
COURT OF SPECIAL APPEALS OF MARYLAND
No. 02621
September Term, 2004
FORENSIC ADVISORS, INC., et al.
Appellants,
vs.
MATRIXX INITIATIVES, INC., et al.
Appellees.
citizen.org
Case Number CV2004-021668 Judge Gaines
Case Type Civil
File Date 11/17/2004
Party Name Rel Sex Attorney
Caron Cappy Plaintiff Female Daniel Radacosky
Dennis Christensen Plaintiff Male Daniel Radacosky
Sharon F Cunningham Plaintiff Female Daniel Radacosky
Lorene Debartolo Plaintiff Female Daniel Radacosky
Cynthia A Dunn Plaintiff Female Daniel Radacosky
Heidi Huglin Deane Plaintiff Female Daniel Radacosky
William C Ladley Plaintiff Male Daniel Radacosky
Shelley Levine Plaintiff Female Daniel Radacosky
Joseph J Martzig Plaintiff Male Daniel Radacosky
Patricia S Meola Plaintiff Female Daniel Radacosky
Roger L Nakata Plaintiff Male Daniel Radacosky
Ruth Robinson Plaintiff Female Daniel Radacosky
Sharyl J Rodina Plaintiff Female Daniel Radacosky
Timothy H Ross Plaintiff Male Daniel Radacosky
Laura L Walker Plaintiff Female Daniel Radacosky
Kenneth W Wigton Plaintiff Male Daniel Radacosky
Gail E Newman Plaintiff Female Daniel Radacosky
Linda H Roark Strummer Plaintiff Female Daniel Radacosky
Matrixx Initiatives Inc Defendant Paul Giancola
Zicam L L C Defendant Paul Giancola
etc ...
superiorcourt.maricopa.gov
Case Number CV2005-002569 Judge Schneider
Case Type Civil
File Date 2/11/2005 Location Downtown
Party Information
Party Name Rel Sex Attorney
Ross T Hudson Plaintiff Male Daniel Radacosky
Irene R Meyers Plaintiff Female Daniel Radacosky
Matrixx Initiatives Inc Defendant Paul Giancola
Zicam L L C Defendant Paul Giancola
superiorcourt.maricopa.gov
SUPERIOR COURT OF ARIZONA
MARICOPA COUNTY
CV 2004-001338 02/16/2005
Docket Code 023 Form V000A Page 2
While the Court does not sit to enforce ethical rules generally, there is no doubt of its inherent authority to regulate the conduct of lawyers who appear before it. Here, the Court finds that Mr. Radacosky’s anonymous, message-board postings were made in connection with the representation of his clients in these pending, consolidated cases. No other conclusion is plausible. Mr. Radacosky’s failure to disclose his role and direct interest in the issues which are
the subject of those message-board postings is, in the Court’s view, a violation of ER 4.1(a)(“Truthfulness in Statements to Others”) and ER 4.3(“Dealing With Unrepresented Person”) and potentially a violation of ER 8.4(c) (“Misconduct”). Without deciding the wisdom of Mr.
Radacosky’s activities or whether those activities conflict with his own clients’ interests, it is clear that his postings have no purpose but to harm a litigation adversary.
The Court’s power to regulate out-of-court conduct of lawyers who appear before it should be exercised with restraint and caution. Exercise of that power should be limited to
circumstances where the integrity of the legal process, the public’s respect for the courts or the litigants’ interests in a fair and untainted proceeding are directly affected. Matrixx and Zicam ask the Court to enter an order either (1) precluding Mr. Radacosky from making further postings
or (2) requiring him to disclose his interest in these cases in any future posting. While the Court is tempted to adopt the latter alternative, it declines to do so at this time and on the record before it for the following reasons:
1. It is not clear to the Court that Matrixx and Zicam do not have a right to identify “painfullyblunt2004” (Mr. Radacosky’s nom de plume) on the Yahoo! Finance Internet message board or any other Internet site. The Court has in mind Matrixx’ counsel’s argument that Matrixx’ rights to
speak are circumscribed by federal securities regulations, but remains to be persuaded that Matrixx
does not have a non-judicial remedy.
2. There is no trial set, and no apparent danger of tainting a prospective jury pool at this time.
3. The harm to Matrixx and Zicam is difficult to assess. The anonymous character of the message board does not reveal the identity of the recipients of Mr. Radacosky’s postings.
They may be, as Matrixx argues, Matrixx shareholders or prospective shareholders, financial analysts or interested members of the public. Absent some more quantifiable or identifiable harm to Matrixx, the Court is reluctant to intrude into the debate reflected by the postings on the
message board.
Nothing in this order should be considered an approval or a justification of Mr. Radacosky’s actions. If any of the three factors identified as a basis for the denial of relief
should change, or if new issues should arise, Matrixx and Zicam may renew their request.
IT IS HEREBY ORDERED denying without prejudice the motion of defendants Matrixx Initiatives, Inc. and Zicam, LLC, for relief.
courtminutes.maricopa.gov
To: Jeffrey S. Mitchell who wrote (7126) 2/18/2005 1:07:50 PM
From: Jeffrey S. Mitchell Read Replies (1) 7370 of 9801
Re: 2/18/05 - [MTXX] Judge Rules Attorney's Failure to Disclose his Identity on Yahoo Violated the Law
Message 21060618
To: Jeffrey S. Mitchell who wrote (7651) 4/13/2005 1:21:56 AM
From: Jeffrey S. Mitchell Read Replies (1) 7961 of 9801
Re: 4/6/05 - [MTXX] Radacosky vs. John Doe
Message 21223168
[jefFREY needs correction -- mtxx sued john doe first in 2002!
superiorcourt.maricopa.gov ]
Message 21223168
Register of Actions/Docket
Case Information Associated Cases
Number: 1-05-CV-044455
Title: D. Radacosky Vs John Doe #1
Category: Other Complaint - Unlimited
Filed: 7/5/2005 Disposed: Status: Open
sccaseinfo.org
July 2005
pointoflaw.com
Daniel J. Radacosky 03-2097, et al. Hearing Officer Report
filed 07/08/05 Disciplinary Commission Report
supremecourt.az.gov
filed 11/14/05 Supreme Court
supremecourt.az.gov
Judgment & Order [pending?]
supremecourt.az.gov
Disciplinary Commission of the Supreme Court of Arizona
Saturday, November 19, 2005
Consideration of the Hearing Officer’s Report recommending transfer to disability inactive status.
supremecourt.az.gov
ATTORNEYS TRANSFERRED TO DISABILITY INACTIVE STATUS - 2005
Radacosky, Daniel J.
05-5001
Indefinite Disability Inactive Status
11/29/05
supreme.state.az.us
veribull gets sued!!!
by: painfullyblunt2004 04/06/05 04:59 pm Msg: 111638
fullofbull is now officially a defendant in a defamation suit. Don't spend all my money golfing,
fullofbull. I don't want to have to execute a judgment on your golf clubs.
messages.finance.yahoo.com
CV2005-005820 Case Type Civil File Date 4/6/2005
superiorcourt.maricopa.gov
From: AsturiasPh.D/MBA
Case Information Case Number CV2005-005820 Judge
Message 21531900
Filed: 7/05/2005 Number: 1-05-CV-044455
sccaseinfo.org
Filed: 7/08/2005
Hearing officers report about a six-count complaint filed November 29, 2004
supremecourt.az.gov
Re: 7/14/05 - [MTXX] Radacosky vs. John Doe: Radacosky Subpoenas Yahoo...
Message 21507468
Re: 7/20/05 - [MTXX] Radacosky vs. John Doe: Radacosky Subpoenas Additional Information from Yahoo
Posters
Message 21533072
To: ravenseye who wrote (360) 2/26/2006 3:50:57 PM
From: AsturiasPh.D/MBA Read Replies (1) 361 of 2479
DANIEL J RADACOSKY ID NOT A DEFENDANT. WHATS YOUR POINT?
DANIEL J RADACOSKY WAS A PLANTIFFS ATTORNEY.
SURE HE MADE SEVERAL HUNDRED THOUSAND FROM THE CASE AND NOW CAN RETIRE IN STYLE.
HE CAN GO BACK TO BEING A ATTORNEY IN THE FUTURE IF HE WANTS TO. HE CURRENTLY IS NOT SUSPENDED
Message 22206257
Disciplinary Commission of the Supreme Court of Arizona
Friday, April 7, 2006
Consideration of the State Bar’s Petition for Order to Show Cause Why Discipline Should Not Proceed.
supremecourt.az.gov
4/18/06
MATRIXX INITIATIVES, INC.,
Plaintiff and Respondent,
v.
JOHN DOE, et. al.,
Defendants;
BARBARY COAST CAPITAL
MANAGEMENT, et. al.,
Appellants.
courtinfo.ca.gov
Metropolitan News-Enterprise
Wednesday, April 19, 2006 Page 1
Witness Must Identify Source of Anonymous Web Postings—C.A.
Justices Say Third Party Lacks Standing to Assert First Amendment Challenge
Matrixx was able to obtain information from Yahoo! tracing Gunallenlies to Worthington’s firm, Barbary Coast Capital Management in the San Francisco Bay Area. At his deposition, which was taken in San Francisco, Worthington refused to answer any questions about Veritasconari and Gunallenlies, including whether he was Veritasconari or Gunallenlies.
Message 22375878
SUPERIOR COURT OF ARIZONA
MARICOPA COUNTY
CV 2005-005820 07/21/2006
Docket Code 023 Form V000A Page 1
CLERK OF THE COURT
HONORABLE BARRY C. SCHNEIDER W. Yank
Deputy
FILED: 07/25/2006
DANIEL J RADACOSKY DANIEL J RADACOSKY
4582 E CHUCHWALLA CANYON
PHOENIX AZ 85044
v.
JOHN DOE, et al.
courtminutes.maricopa.gov
3300.00 to the Federal Election Commission
RADACOSKY, DANIEL PHOENIX
AZ 85044 06/07/2006 1000.00 SELF-EMPLOYED/ATTORNEY 26020401818
query.nictusa.com
08/02/2006
IT IS ORDERED:
1. Vacating the status conference set in this division on August 8, 2006.
2. Setting a telephonic status conference in this division on November 9, 2006
at 9:00 a.m. Counsel for the Plaintiff is to initiate the telephonic conference
by first arranging the presence of all other counsel or self-represented parties
on the conference call and by calling this division (602-506-3940) promptly at
the scheduled time.
3. At the initiative of counsel for Matrixx, a brief joint report will be filed with
this division not later than noon on November 2, 2006.
Let the record reflect that this minute entry is faxed to counsel this date.
courtminutes.maricopa.gov
courtminutes.maricopa.gov
9/21/06
Still, the appeals court in Annapolis upheld the subpoena, stating that Mulligan's deposition would "go forward because it is clear that the subpoena issued to appellants [Mulligan] seeks much more information than is subject to protection under the act," wrote Chief Judge Joseph Murphy, referring to the state shield law.
rcfp.org
throw Milberg Weiss into the mix and this seems more volatile than first thought!
coldcure.com
george-eby-research.com
sure would be something if this turns into a securities manipulation case!
lma(zz)o who is fooling who?
yahoo.brand.edgar-online.com
lma(zz)o |
| | MTXX FORMERLY GUMM. CURE OR OUTRIGHT SCAM? | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
